Mark Pruzanski, Intercept CEO (GlobeNewswire via YouTube)
September 1, 2020 05:14 PM EDT
Pharma

Spurned by the FDA, In­ter­cept brings out the bud­get axe and chops 170 jobs

John Carroll

Editor & Founder

The un­ex­pect­ed CRL that land­ed at In­ter­cept Phar­ma­ceu­ti­cals $ICPT 2 months ago is cost­ing the biotech dear­ly.

In an SEC

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

PDU­FAs for Tonix and Nu­va­tion; Sanofi vac­cine part­ner­ship; RAPT al­ler­gy deal

A service from the Financial Times